Document is current
Any future updates will be listed below
-
Authors
Santaliestra, Marta
Garrote, Marta https://orcid.org/0000-0001-8571-1466
Noya, María Soledad https://orcid.org/0009-0008-4875-3438
Pérez-Encinas, Manuel
Senín, Alicia
Pérez-López, Raúl
Ferrer-Marín, Francisca https://orcid.org/0000-0002-9520-3243
Carreño-Tarragona, Gonzalo https://orcid.org/0000-0002-9570-5542
Caballero, Gonzalo
Magro, Elena
Vélez, Patricia
Cortés Vázquez, Miguel Ángel
Moretó, Ana
Angona, Anna
Pastor-Galán, Irene
Guerra, José María
García Hernández, Carmen
Mata, María Isabel
Stuckey, Ruth https://orcid.org/0000-0001-6955-2290
Gómez-Casares, María Teresa https://orcid.org/0000-0003-0505-5126
Fox, Laura
Cuevas, Beatriz https://orcid.org/0000-0001-7555-3361
García-Gutiérrez, Valentín https://orcid.org/0000-0003-4752-0815
Triguero, Ana
Arellano-Rodrigo, Eduardo https://orcid.org/0000-0001-6236-7826
Hernández-Boluda, Juan Carlos https://orcid.org/0000-0002-4289-3113
Alvarez-Larrán, Alberto https://orcid.org/0000-0001-6387-4619
- License Information
-
More Information
Article History
Received: 12 July 2024
Revised: 8 September 2024
Accepted: 16 September 2024
First Online: 27 September 2024
Competing interests
: The Spanish registry of Essential thrombocythemia is financed with GEMFIN’s own funds without direct collaboration from any pharmaceutical company. This work has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI21/00231, PI21/00347, and PI21/00538 and co-funded by the European Union.
